

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Heinz KOHLER

Invention: FUSION PROTEINS OF BIOLOGICALLY ACTIVE
PEPTIDES AND ANTIBODIES

ANTONELLI, TERRY, STOUT & KRAUS, LLP
1300 North Seventeenth Street
Suite 1800
Arlington, VA 22209

SPECIFICATION

To all whom it may concern:

Be it known that I, Heinz KOHLER, residing at 5235
Athens Boonesboro Road, Lexington, Kentucky, 40509, have
invented new and useful improvements in FUSION PROTEINS
OF BIOLOGICALLY ACTIVE PEPTIDES AND ANTIBODIES, of which
the following is a specification.

SEARCHED
INDEXED
MAILED
FILED

FUSION PROTEINS OF BIOLOGICALLY ACTIVE PEPTIDES AND
ANTIBODIES

CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a continuation-in-part of
5 U.S. Patent Application Serial No. 09/070,907, filed May
4, 1998, the disclosure of which is incorporated herein
by reference.

FIELD OF THE INVENTION

10 The present invention relates to fusion proteins of
biologically active peptides and antibodies.
Specifically, the fusion proteins of the present
invention combine the molecular recognition of antibodies
with a biological activity such as immunostimulatory
15 activity, membrane transport activity, and homophilic
activity.

BACKGROUND OF THE INVENTION

Antibodies have been praised as "magic bullets" to
combat disease. However, the promises made for antibodies
20 were never fully realized. This is in part due to the fact
that antibodies represent only one arm of the immune
defense, where T-cells provide the other strategy in
immune defense. However, antibodies are ideal targeting
and delivery devices. They are adapted for long survival
25 in blood, have sites which help vascular and tissue
penetration and are functionally linked with a number of
defense mechanisms of the innate immunity. One such

09/070,907
10/070,907
11/070,907
12/070,907
13/070,907
14/070,907
15/070,907
16/070,907
17/070,907
18/070,907
19/070,907
20/070,907
21/070,907
22/070,907
23/070,907
24/070,907
25/070,907
26/070,907
27/070,907
28/070,907
29/070,907
30/070,907
31/070,907
32/070,907
33/070,907
34/070,907
35/070,907
36/070,907
37/070,907
38/070,907
39/070,907
40/070,907
41/070,907
42/070,907
43/070,907
44/070,907
45/070,907
46/070,907
47/070,907
48/070,907
49/070,907
50/070,907
51/070,907
52/070,907
53/070,907
54/070,907
55/070,907
56/070,907
57/070,907
58/070,907
59/070,907
60/070,907
61/070,907
62/070,907
63/070,907
64/070,907
65/070,907
66/070,907
67/070,907
68/070,907
69/070,907
70/070,907
71/070,907
72/070,907
73/070,907
74/070,907
75/070,907
76/070,907
77/070,907
78/070,907
79/070,907
80/070,907
81/070,907
82/070,907
83/070,907
84/070,907
85/070,907
86/070,907
87/070,907
88/070,907
89/070,907
90/070,907
91/070,907
92/070,907
93/070,907
94/070,907
95/070,907
96/070,907
97/070,907
98/070,907
99/070,907
100/070,907
101/070,907
102/070,907
103/070,907
104/070,907
105/070,907
106/070,907
107/070,907
108/070,907
109/070,907
110/070,907
111/070,907
112/070,907
113/070,907
114/070,907
115/070,907
116/070,907
117/070,907
118/070,907
119/070,907
120/070,907
121/070,907
122/070,907
123/070,907
124/070,907
125/070,907
126/070,907
127/070,907
128/070,907
129/070,907
130/070,907
131/070,907
132/070,907
133/070,907
134/070,907
135/070,907
136/070,907
137/070,907
138/070,907
139/070,907
140/070,907
141/070,907
142/070,907
143/070,907
144/070,907
145/070,907
146/070,907
147/070,907
148/070,907
149/070,907
150/070,907
151/070,907
152/070,907
153/070,907
154/070,907
155/070,907
156/070,907
157/070,907
158/070,907
159/070,907
160/070,907
161/070,907
162/070,907
163/070,907
164/070,907
165/070,907
166/070,907
167/070,907
168/070,907
169/070,907
170/070,907
171/070,907
172/070,907
173/070,907
174/070,907
175/070,907
176/070,907
177/070,907
178/070,907
179/070,907
180/070,907
181/070,907
182/070,907
183/070,907
184/070,907
185/070,907
186/070,907
187/070,907
188/070,907
189/070,907
190/070,907
191/070,907
192/070,907
193/070,907
194/070,907
195/070,907
196/070,907
197/070,907
198/070,907
199/070,907
200/070,907
201/070,907
202/070,907
203/070,907
204/070,907
205/070,907
206/070,907
207/070,907
208/070,907
209/070,907
210/070,907
211/070,907
212/070,907
213/070,907
214/070,907
215/070,907
216/070,907
217/070,907
218/070,907
219/070,907
220/070,907
221/070,907
222/070,907
223/070,907
224/070,907
225/070,907
226/070,907
227/070,907
228/070,907
229/070,907
230/070,907
231/070,907
232/070,907
233/070,907
234/070,907
235/070,907
236/070,907
237/070,907
238/070,907
239/070,907
240/070,907
241/070,907
242/070,907
243/070,907
244/070,907
245/070,907
246/070,907
247/070,907
248/070,907
249/070,907
250/070,907
251/070,907
252/070,907
253/070,907
254/070,907
255/070,907
256/070,907
257/070,907
258/070,907
259/070,907
260/070,907
261/070,907
262/070,907
263/070,907
264/070,907
265/070,907
266/070,907
267/070,907
268/070,907
269/070,907
270/070,907
271/070,907
272/070,907
273/070,907
274/070,907
275/070,907
276/070,907
277/070,907
278/070,907
279/070,907
280/070,907
281/070,907
282/070,907
283/070,907
284/070,907
285/070,907
286/070,907
287/070,907
288/070,907
289/070,907
290/070,907
291/070,907
292/070,907
293/070,907
294/070,907
295/070,907
296/070,907
297/070,907
298/070,907
299/070,907
300/070,907
301/070,907
302/070,907
303/070,907
304/070,907
305/070,907
306/070,907
307/070,907
308/070,907
309/070,907
310/070,907
311/070,907
312/070,907
313/070,907
314/070,907
315/070,907
316/070,907
317/070,907
318/070,907
319/070,907
320/070,907
321/070,907
322/070,907
323/070,907
324/070,907
325/070,907
326/070,907
327/070,907
328/070,907
329/070,907
330/070,907
331/070,907
332/070,907
333/070,907
334/070,907
335/070,907
336/070,907
337/070,907
338/070,907
339/070,907
340/070,907
341/070,907
342/070,907
343/070,907
344/070,907
345/070,907
346/070,907
347/070,907
348/070,907
349/070,907
350/070,907
351/070,907
352/070,907
353/070,907
354/070,907
355/070,907
356/070,907
357/070,907
358/070,907
359/070,907
360/070,907
361/070,907
362/070,907
363/070,907
364/070,907
365/070,907
366/070,907
367/070,907
368/070,907
369/070,907
370/070,907
371/070,907
372/070,907
373/070,907
374/070,907
375/070,907
376/070,907
377/070,907
378/070,907
379/070,907
380/070,907
381/070,907
382/070,907
383/070,907
384/070,907
385/070,907
386/070,907
387/070,907
388/070,907
389/070,907
390/070,907
391/070,907
392/070,907
393/070,907
394/070,907
395/070,907
396/070,907
397/070,907
398/070,907
399/070,907
400/070,907
401/070,907
402/070,907
403/070,907
404/070,907
405/070,907
406/070,907
407/070,907
408/070,907
409/070,907
410/070,907
411/070,907
412/070,907
413/070,907
414/070,907
415/070,907
416/070,907
417/070,907
418/070,907
419/070,907
420/070,907
421/070,907
422/070,907
423/070,907
424/070,907
425/070,907
426/070,907
427/070,907
428/070,907
429/070,907
430/070,907
431/070,907
432/070,907
433/070,907
434/070,907
435/070,907
436/070,907
437/070,907
438/070,907
439/070,907
440/070,907
441/070,907
442/070,907
443/070,907
444/070,907
445/070,907
446/070,907
447/070,907
448/070,907
449/070,907
450/070,907
451/070,907
452/070,907
453/070,907
454/070,907
455/070,907
456/070,907
457/070,907
458/070,907
459/070,907
460/070,907
461/070,907
462/070,907
463/070,907
464/070,907
465/070,907
466/070,907
467/070,907
468/070,907
469/070,907
470/070,907
471/070,907
472/070,907
473/070,907
474/070,907
475/070,907
476/070,907
477/070,907
478/070,907
479/070,907
480/070,907
481/070,907
482/070,907
483/070,907
484/070,907
485/070,907
486/070,907
487/070,907
488/070,907
489/070,907
490/070,907
491/070,907
492/070,907
493/070,907
494/070,907
495/070,907
496/070,907
497/070,907
498/070,907
499/070,907
500/070,907
501/070,907
502/070,907
503/070,907
504/070,907
505/070,907
506/070,907
507/070,907
508/070,907
509/070,907
510/070,907
511/070,907
512/070,907
513/070,907
514/070,907
515/070,907
516/070,907
517/070,907
518/070,907
519/070,907
520/070,907
521/070,907
522/070,907
523/070,907
524/070,907
525/070,907
526/070,907
527/070,907
528/070,907
529/070,907
530/070,907
531/070,907
532/070,907
533/070,907
534/070,907
535/070,907
536/070,907
537/070,907
538/070,907
539/070,907
540/070,907
541/070,907
542/070,907
543/070,907
544/070,907
545/070,907
546/070,907
547/070,907
548/070,907
549/070,907
550/070,907
551/070,907
552/070,907
553/070,907
554/070,907
555/070,907
556/070,907
557/070,907
558/070,907
559/070,907
560/070,907
561/070,907
562/070,907
563/070,907
564/070,907
565/070,907
566/070,907
567/070,907
568/070,907
569/070,907
570/070,907
571/070,907
572/070,907
573/070,907
574/070,907
575/070,907
576/070,907
577/070,907
578/070,907
579/070,907
580/070,907
581/070,907
582/070,907
583/070,907
584/070,907
585/070,907
586/070,907
587/070,907
588/070,907
589/070,907
590/070,907
591/070,907
592/070,907
593/070,907
594/070,907
595/070,907
596/070,907
597/070,907
598/070,907
599/070,907
600/070,907
601/070,907
602/070,907
603/070,907
604/070,907
605/070,907
606/070,907
607/070,907
608/070,907
609/070,907
610/070,907
611/070,907
612/070,907
613/070,907
614/070,907
615/070,907
616/070,907
617/070,907
618/070,907
619/070,907
620/070,907
621/070,907
622/070,907
623/070,907
624/070,907
625/070,907
626/070,907
627/070,907
628/070,907
629/070,907
630/070,907
631/070,907
632/070,907
633/070,907
634/070,907
635/070,907
636/070,907
637/070,907
638/070,907
639/070,907
640/070,907
641/070,907
642/070,907
643/070,907
644/070,907
645/070,907
646/070,907
647/070,907
648/070,907
649/070,907
650/070,907
651/070,907
652/070,907
653/070,907
654/070,907
655/070,907
656/070,907
657/070,907
658/070,907
659/070,907
660/070,907
661/070,907
662/070,907
663/070,907
664/070,907
665/070,907
666/070,907
667/070,907
668/070,907
669/070,907
670/070,907
671/070,907
672/070,907
673/070,907
674/070,907
675/070,907
676/070,907
677/070,907
678/070,907
679/070,907
680/070,907
681/070,907
682/070,907
683/070,907
684/070,907
685/070,907
686/070,907
687/070,907
688/070,907
689/070,907
690/070,907
691/070,907
692/070,907
693/070,907
694/070,907
695/070,907
696/070,907
697/070,907
698/070,907
699/070,907
700/070,907
701/070,907
702/070,907
703/070,907
704/070,907
705/070,907
706/070,907
707/070,907
708/070,907
709/070,907
710/070,907
711/070,907
712/070,907
713/070,907
714/070,907
715/070,907
716/070,907
717/070,907
718/070,907
719/070,907
720/070,907
721/070,907
722/070,907
723/070,907
724/070,907
725/070,907
726/070,907
727/070,907
728/070,907
729/070,907
730/070,907
731/070,907
732/070,907
733/070,907
734/070,907
735/070,907
736/070,907
737/070,907
738/070,907
739/070,907
740/070,907
741/070,907
742/070,907
743/070,907
744/070,907
745/070,907
746/070,907
747/070,907
748/070,907
749/070,907
750/070,907
751/070,907
752/070,907
753/070,907
754/070,907
755/070,907
756/070,907
757/070,907
758/070,907
759/070,907
760/070,907
761/070,907
762/070,907
763/070,907
764/070,907
765/070,907
766/070,907
767/070,907
768/070,907
769/070,907
770/070,907
771/070,907
772/070,907
773/070,907
774/070,907
775/070,907
776/070,907
777/070,907
778/070,907
779/070,907
780/070,907
781/070,907
782/070,907
783/070,907
784/070,907
785/070,907
786/070,907
787/070,907
788/070,907
789/070,907
790/070,907
791/070,907
792/070,907
793/070,907
794/070,907
795/070,907
796/070,907
797/070,907
798/070,907
799/070,907
800/070,907
801/070,907
802/070,907
803/070,907
804/070,907
805/070,907
806/070,907
807/070,907
808/070,907
809/070,907
810/070,907
811/070,907
812/070,907
813/070,907
814/070,907
815/070,907
816/070,907
817/070,907
818/070,907
819/070,907
820/070,907
821/070,907
822/070,907
823/070,907
824/070,907
825/070,907
826/070,907
827/070,907
828/070,907
829/070,907
830/070,907
831/070,907
832/070,907
833/070,907
834/070,907
835/070,907
836/070,907
837/070,907
838/070,907
839/070,907
840/070,907
841/070,907
842/070,907
843/070,907
844/070,907
845/070,907
846/070,907
847/070,907
848/070,907

mechanism is the complement system which helps to destroy pathogens and is involved in the regulation of immune responses. For example the complement fragment C3d binds to the CR2 receptor on B-cells, which is also the binding site for Epstein-Barr virus. Binding of Epstein-Barr virus to CR2 activates B-cells. Accumulated evidence has shown that the CR2 receptor (CD19/Cd20/CD81 complex) has an immuno-stimulatory role and is activated by C3d.

Another example of how antibodies can be used to enhance the immune response has been demonstrated by the work of Zanetti and Bona (Zanetti, M. Nature 355: 466-477, 1992; Zaghouani H.; Anderson S.A., Sperber K.E., Daian C. Kennedy R.C., Mayer L. and Bona C.A. 1995 Proc. Nat. Acad. Science U.S. 92: 631-635). These authors have replaced the CDR3 sequence of the Ig heavy chain with a sequence resembling T-cell and B-cell antigens (epitopes) using molecular biology methods and have shown that these modified antibodies induce potent immune response specific for the inserted groups.

The biological properties of the antibodies can be enhanced with respect to overall avidity for antigen and the ability to penetrate cellular and nuclear membranes. Antigen binding is enhanced by increasing the valency of antibodies such as in pentameric IgM antibodies. Valency and avidity is also increased in certain antibodies which are self binding or homophilic (Kang, C.Y., Cheng, H.L., Rudikoff, S. and Kohler, H. J. Exp. Med. 165:1332, 1987). Xiyun, A.N., Evans, S.V., Kaminki, M.J., Fillies, S.F.D.,

Resifeld, R.A., Noughton, A.N. and Chapman, P.B. J. Immunol. 157: 1582-1588 (1996)). A peptide in the heavy chain variable region was identified which inhibited self-binding (Kang, C.Y. Brunck, T.K., Kieber-Emmons, T., Blalock, J.E. and Kohler, H., Science, 240: 1034-1036, 1988). The insertion of self-binding peptide sequence into an antibody endows the property of self-binding and increases the valency and overall avidity for the antigen.

Similarly the addition of a signal peptide to antibodies facilitates transmembrane transport as demonstrate by Rojas et al, Nature Biotechnology, 16: 370-375 (1998). Rojas et al. have generated a fusion protein which contained a 12 mer peptide and have shown that this protein has cell membrane permeability.

Antibodies have been used as delivery devices for several biologically active molecules, such as toxins, drugs and cytokines. Often fragments of antibodies, Fab or scFv, are preferred because of better tissue penetration and reduced "stickiness".

There are two practical methods for attaching molecules such as peptides to antibody molecules. One method is to use chemical crosslinking, such as the affinity-crosslinking method described in co-pending application Serial No. 09/070,907. Another method is to design a fusion gene containing DNA encoding the antibody and the peptide and to express the fusion gene, which method is the subject of the present application.

Antibody fusion proteins have typically been engineered with entire genes of large proteins or domains of such proteins that produce a biological function. Small peptide-antibody fusion proteins are typically made to facilitate the purification or characterization of the antibody.

Methods of creating fusion proteins are described, for example, in the following U.S. patents, incorporated herein by reference: U.S. Patent No. 5,563,046 to Mascarenhas et al; U.S. Patent No. 5,645,835 to Fell, Jr.; U.S. Patent No. 5,668,225 to Murphy; U.S. Patent No. 5,698,679 to Nemazee; U.S. Patent No. 5,763,733 to Whitlow et al; U.S. Patent No. 5,811,265 to Quertermous et al; U.S. Patent No. 5,908,626 to Chang et al; U.S. Patent No. 5,969,109 to Bona et al; U.S. Patent No. 6,008,319 to Epstein et al; U.S. Patent No. 6,117,656 to Seed; U.S. Patent No. 6,121,424 to Whitlow et al; U.S. Patent No. 6,132,992 to Ledbetter et al; U.S. Patent No. 6,207,804 to Huston et al; and U.S. Patent No. 6,224,870 to Segal. Methods of creating Ig fusion proteins are described, for example, in Antibody Engineering, 2nd Edition. ed.: Carl A.K. Borrebaeck, Oxford University Press 1995, and in "Molecular Cloning: A Laboratory Manual, Second Ed., Cold Spring Harbor Press, 1989, incorporated herein by reference.

SUMMARY OF THE INVENTION

The present invention provides a fusion protein

comprising an antibody and a peptide having a biological activity selected from the group consisting of immuno-stimulatory, membrane transport and homophilic activities, wherein the peptide is located at a site in
5 the antibody so that the incorporated peptide does not compromise the antigen recognition of the antibody. In the present invention, this is accomplished by a method comprising the steps of creating a fusion gene comprising a nucleic acid sequence encoding an antibody and a
10 nucleic acid sequence encoding the peptide, wherein the nucleic acid sequence encoding the peptide is located inside the nucleic acid sequence encoding the antibody at a site wherein, when the fusion is expressed, the fusion protein that is created thereby includes the antibody plus the peptide, and the peptide is connected to the antibody at a site that does not interfere with antigen binding of the antibody, and expressing the fusion gene to create the fusion protein. In particular, the fusion protein may be created by providing a gene encoding an
15 antibody, wherein the gene is mutated to contain a restriction site, wherein the restriction site is located away from any section of the gene that encodes an antigen-binding site of the antibody, inserting a DNA sequence encoding a peptide having a biological activity
20 selected from the group consisting of immuno-stimulatory, membrane transport and homophilic activities into restriction site of the gene encoding the antibody to create a fusion gene, and wherein the DNA sequence
25

encoding the peptide is inserted so that it is in-frame with the gene encoding the antibody, and expressing the fusion gene to create a fusion protein.

5 The invention also provides a composition and a pharmaceutical composition comprising a fusion protein of a peptide having a biological activity selected from the group consisting of immuno-stimulatory, membrane transport and homophilic activities and an antibody.

10 The invention of creating fusion proteins of biologically active peptides and antibodies includes peptides which comprise self-binding, stimulate lymphocytes and allow transport across biological membranes.

15 The above and other objects of the invention will become readily apparent to those of skill in the relevant art from the following detailed description and figures, wherein only the preferred embodiments of the invention are shown and described, simply by way of illustration of the best mode of carrying out the invention. As is 20 readily recognized the invention is capable of modifications within the skill of the relevant art without departing from the spirit and scope of the invention.

DETAILED DESCRIPTION OF THE INVENTION

25 The present invention describes a method for creating fusion proteins of an antibody and a peptide having a biological activity selected from the group consisting of

immuno-stimulatory, membrane transport and homophilic activities.

In particular, the present invention provides a fusion protein comprising an antibody and a peptide having a 5 biological activity selected from the group consisting of immuno-stimulatory, membrane transport and homophilic activities, wherein the peptide is located at a site in the antibody so that the incorporated peptide does not compromise the antigen recognition of the antibody. In 10 the present invention, this is accomplished by a method comprising the steps of creating a fusion gene comprising a nucleic acid sequence encoding an antibody and a nucleic acid sequence encoding the peptide, wherein the nucleic acid sequence encoding the peptide is located 15 inside the nucleic acid sequence encoding the antibody at a site wherein, when the fusion is expressed, the fusion protein that is created thereby includes the antibody plus the peptide, and the peptide is connected to the antibody at a site that does not interfere with antigen 20 binding of the antibody, and expressing the fusion gene to create the fusion protein. In particular, the fusion protein may be created by providing a gene encoding an antibody, wherein the gene is mutated to contain a restriction site, wherein the restriction site is located 25 away from any section of the gene that encodes an antigen-binding site of the antibody, inserting a DNA sequence encoding a peptide having a biological activity selected from the group consisting of immuno-stimulatory,

membrane transport and homophilic activities into
restriction site of the gene encoding the antibody to
create a fusion gene, and wherein the DNA sequence
encoding the peptide is inserted so that it is in-frame
5 with the gene encoding the antibody, and expressing the
fusion gene to create a fusion protein.

**The Expression of Ig-fusion Proteins (adapted from
Antibody Engineering, 2nd Edition. ed.: Carl A.K.
Borrebaeck, Oxford University Press 1995)**

10 Ig fusion proteins have the advantage of joining the antibody combining specificity and/or antibody effector functions with molecules contributing unique properties. The ability to produce this family of proteins was first demonstrated when c-myc was substituted for the Fc of the antibody molecule, (Neuberger MS, Williams GT and Fox RO. Nature 125:604, 1984) but many examples now exist. Ab fusion proteins can be achieved in several different ways. In one approach non-Ig sequences are substituted for the variable region; the molecule replacing the V
15 region provides specificity of targeting with the antibody contributing properties such as effector functions and improved pharmacokinetics. Examples include IL-2 and CD4. Alternatively, non-Ig
20 sequences can be substituted for or attached to the constant region. The resulting molecules retain the binding specificity of the original antibody but gain characteristics from the attached protein. Depending on
25 the position of the substitution, different antibody-

related effector functions and biologic properties will be retained.

Vectors for the Construction of IgG Fusion Proteins

A series of vectors has now been produced that permits 5 the fusion of proteins at different positions within an antibody molecule, thereby facilitating the construction of fusion proteins with different properties. Using these vectors it is possible to produce a family of fusion proteins with molecules of differing molecular weight, 10 valence, and having different subsets of the functional properties of the antibody molecule.

As a specific example of how to facilitate the construction of fused genes, site-directed mutagenesis was used to generate unique restriction enzyme sites in 15 the human IgG3 heavy chain gene. In this particular example, restriction sites were generated at the 3' end of the CH1 exon, immediately after the hinge at the 5' end of the CH2 exon, and at the 3' end of the CH3 exon. The restriction sites thus produced were SnaB I at the 20 end of CH1 by replacing TtgGTg with TacGta, Pvu II at the beginning of CH2 by replacing CAcCTG with CAgCTG, and Ssp I at the end of CH3 replacing AATgag with AATatt. These manipulations provided a unique blunt-end cloning site at these positions. In all cases the restriction site was 25 positioned so that after cleavage the Ig would contribute the first base of the codon. Human IgG3 with an extended hinge region of 62 amino acids was chosen for use as the

immunoglobulin; when present this hinge should provide spacing and flexibility, thereby facilitating simultaneous antigen and receptor binding. An EcoR I site was also introduced at 3' of the IgG3 gene to provide a 5 3' cloning site and polyA addition signal. Although initially designed for use with growth factors, these 10 restrictions sites can be used to position any novel sequence at defined positions in the antibody. Also, using these cloning cassettes the variable region can easily be changed. Similar techniques may be used to generate suitable restriction sites in other antibody 15 genes.

Production of A Fusion Gene

As a first step in the production of a fusion 15 protein, a blunt-end restriction site must be introduced at the desired position into the 5' end of the gene to be fused. In order to maintain the correct reading frame, the site must be positioned so that after cleavage it will contribute two bases to the codon. If the objective 20 is to make a fusion protein with the complete molecule, the restriction site is usually introduced at the position of any post-translational processing, such as after the leader sequence. Alternatively, if the objective is to use only a portion of the protein, the 25 blunt-end site can be introduced at any position within the gene, but attention must always be paid to maintaining the correct reading frame. Additionally, if

there is carboxylterminal post-translational processing of the fused protein, it is frequently desirable to introduce a stop-codon at this processing site.

A major concern when producing fusion proteins is maintaining the biologic activities of all of the components. The production of fusion proteins with antibodies is facilitated by the domain structure of the antibody, and all of the cloning sites have been positioned immediately following an intact domain. In this configuration the correct folding of the immunoglobulin should be assured. The folding of the attached protein depends on its structure and where it is fused. Whenever structural information is available, it is desirable to produce the fusion at a position that will maintain the structural integrity of the attached protein.

To produce quantities of protein sufficient for functional analysis, it is desirable to have the protein secreted into the medium. While in the examples reported to date, assembled fusion proteins have been assembled and secreted, this remains a concern when designing additional fusion proteins.

The method to design a fusion gene that contains a biologically activity peptide as part of the heavy or light chain gene can use established antibody engineering protocols (Antibody Engineering, 2nd Edition. ed.: Carl A.K. Borrebaeck, Oxford University Press 1995. Chapter 9, pages 267-293). The peptide can fused either to N-terminal

residues or the C-terminal residues of H or L chains. The expression of such fused genes is typically done in mammalian cell lines, although other expression systems, such as, for example, bacteria or yeast expression systems, may be used.

The peptide of the invention has a biological activity selected from the group consisting of immuno-stimulatory, membrane transport and homophilic activities. Examples include immuno-stimulatory or immuno-regulatory activity.

The peptide may, for example, be a hormone, ligand for cytokines or a binding site derived from natural ligands for cellular receptors. In a preferred embodiment the peptide is derived from C3d region 1217-1232 and ranges from about 10 to about 16 mer. In an alternative embodiment the peptide is a 16mer peptide derived from the C3d region 1217-1232.

The peptide may be bound to an antibody which is a full-length immunoglobulin molecule or a variable domain fragment of an antibody. As used herein, the term "antibody" refers generally to a heavy or light chain immunoglobulin molecule or any function combination or fragment thereof containing an antigen binding site. The antibody is preferably specific for a cellular receptor, on a membrane structure such as a protein, glycoprotein, polysaccharide or carbohydrate, and on a normal cell or on tumor cells.

The use of peptides derived from the ligand site of C3d as an immunostimulatory component incorporated into

antibodies has an unexpected utility as a molecular adjuvant. C3d has been used as molecular adjuvant as part of a complete fusion protein with hen egg lysozyme (HEL) by D. Fearon, et al., (Dempsey, P.W., Allison, M.E.D., 5 Akkaraju, S., Goodnow, C.C. and Fearon, D.T., *Science*, 271:348, 1996). These authors have shown that a HEL- C3d fusion protein is up to 10,000 fold more immunogenic than free HEL (see International Patent Publication, WO96/17625).

10 Similar increases in immunogenicity have been observed with chemical cross-linked idiotype vaccines using a peptide derived from the C3d fragment in our recent animal studies (see examples below). It is believed that attaching C3d peptides to idiotype and anti-idiotype vaccines enhances the immunogenicity of these vaccines and substitutes for the need of attaching carrier molecules such as KLH in combination with strong adjuvants such Freund adjuvant which is not permitted by the FDA for humans.

15 20 In an alternative embodiment, the peptide may be derived from a human or non-human C3d region homologous to the human C3d residues at position 1217-1232 and ranges from about 10 to about 16 mer.

25 Other applications of affinity cross-linking biologically active peptides to antibody vaccines include active peptides derived from cytokines. For example, a nonapeptide from the IL1-beta cytokine has been described (Antoni, et al., *J. Immunol*, 137:3201-04, 1986) which has

immunostimulatory properties without inducing undesired side effects. Other examples of active peptides which can be inserted into antibodies in accordance with the invention include signal peptides, and peptides from the 5 selfbinding locus of antibodies.

A variety of peptides are known having biological activities as hormones, ligands for cytokines or binding sites derived from natural ligands for cellular receptors.

10 **EXAMPLES**

The following examples 1 - 3, while relating to C3d/antibody complexes that are created by affinity cross-linking, are provided to show the effects on the immune response provided by C3d peptides linked to 15 antibodies.

EXAMPLE 1

Enhancement of an anti-idiotype vaccine.

3H1 is a murine anti-idiotype antibody (Bhattacharya-Chatterjee, et al., *J. Immunol.*, 145:2758-65, 1990) which 20 mimics the carcino-embryonic antigen (CEA). 3H1 induces in animals anti-CEA antibodies when used as KLH-conjugated vaccine in complete Freund's adjuvant. 3H1 has also been tested in a clinical phase I study where it induces antibodies which bind to CEA in approximately 25 half of treated cancer patients. However no clinical response was observed in this study (Foon, et al., *J.*

Clin. Invst., 96:334-342, 1995) due, in part, to low immunogenicity.

3H1 mAb was affinity cross-linked with a 13mer peptide (SEQ ID NO.:1) derived from the C3d region 1217-1232. The 5 amino acid sequence was derived from of the Cd3 peptide and has the following sequence (SEQ ID NO. 1):KNRWEDPGKQLYNVEA-. BALB/c mice were immunized twice with 25 μ g of C3d-3H1 in phosphate-saline solution intramuscular. 7 days after the last immunization mice 10 were bled and sera were tested for binding to 8019 (Ab1 idiotype) and to the CEA expressing tumor line LS174T. As determined by FACS, sera from C3d-3H1 immune mice bind to LS174T tumor cells, while a control serum (normal mouse serum) showed only background fluorescence. Sera from 15 mice immunized with C3d-3H1 were used in FACS of LS174T cells in a sandwich assay developed with FITC conjugated goat anti-mouse IgG. Control was a normal mouse serum. Cell number analyzed were plotted against relative fluorescence intensity on log10 scale.

20 **EXAMPLE 2**

Furthermore, sera from mice immunized three times with either 3H1 (25 microgram in saline) or 3H1-C3d-peptide (affinity cross-linked, 25 microgram in saline) were also tested for Ab3 response. Mice were bled and sera were 25 tested for binding to F(ab) of 3H1 in ELISA. Upon determining the binding of dilutions of mouse sera to 3H1 F(ab), it was found that while naked 3H1 does not induce

Ab3 antibodies, 3H1-peptide does showing that the affinity-cross-linked 3H1 enhanced immunogenicity.

Other C3d peptides which may be used in the practice of the present invention include those reviewed in Lambris et al, "Phylogeny of the third component of complement, C3" in Erfi, A ed. New Aspects of Complement structure and function, Austin, R.D. Landes Co., 1994 p. 15-34, incorporated herein by reference in its entirety.

EXAMPLE 3

10 Enhancement of an mouse Tumor Idiotype Vaccine (38C13).

38C13 is the idiotype expressed by the 38C13 B-lymphoma tumor cell line. The Levy group has developed this idiotype tumor vaccine model and has shown that pre-immunization with KLH-conjugated 38C13 Id can protect 15 against challenge with 38C13 tumor cells in mice (Kaminski, M.S., Kitamura, K., Maloney, D.G. and Levy, R., *J. Immunol.*, 138:1289, 1987). Levy and colleagues (Tao, M-H. and Levy, R., *Nature* 362:755-758, 1993) have also reported on the induction of tumor protection using 20 a fusion protein (CSF-38C13), generated from a chimeric gene and expressed in mammalian cell culture fermentation. 38C13 Id proteins was affinity cross-linked with a 16mer azido-peptide derived from the C3D region 1217-1232.

25 10 mice were immunized with 50ug of C3d-38C13 conjugate in phosphate-saline solution intraperitoneally three times. After the third vaccination mice were

challenge with 38C13 tumor cells. Control groups included mice vaccinated with 38C13-KLH in QS-21 (adjuvant), considered the "gold standard" in this tumor model, and mice injected with QS-21 alone. 7 out 10 mice vaccinated 5 with the C3d-38C13 conjugate survived by day 35 after tumor challenge, as did mice vaccinated with the KLH-38C13 in QS-21. All control mice injected only with QS-21 had died by day 22.

10 C3H mice were immunized three times with either 38C13-KLH in QS-21 or with 38C13-C3d peptide without QS-21 (50 ug i.p.) Control mice were only injected with QS-21. Immunized and control mice were than challenged with 38C13 tumor cells and survival was monitored.

15 Results described in Examples 1 - 3 show that affinity-cross-linking of an immuno-stimulatory peptide to tumor anti-idiotype and idiotype vaccine antibodies can significantly enhance the immune response to the tumor and protect against tumor challenge. The 20 vaccination protocol with the C3d-cross-linked vaccine did not include any adjuvant, such as Freund's adjuvant, or KLH conjugation, both of which are not permissible by the FDA for human use.

25 Some of the procedures used in the above examples are known; The active binding peptide of C3d (complement fragment) has been described by Lambris, et al., (PNAS, 82:4235-39, 1985) and is incorporated herein by reference in its entirety.

The following additional examples are provided to

demonstrate the general technique of creating fusion proteins and to illustrate particular peptide having a biological activity selected from the group consisting of immuno-stimulatory, membrane transport and homophilic activities.

5

Example 4:

Fusion non-Ig Protein containing a Membrane Transferring Peptide (MTS-peptide) taken from Rojas, M, Donahue, JP, Tan, T. and Lin, Y-Z. *Nature Biotechnology*, 16: 370, 10 1998. Construction of the glutathion S-transferase-MTS peptide (GST-MTS) expression plasmids.

Two different GST-MTS expression plasmids were constructed so that, depending on the biological application, a target protein or protein domain could be produced with the hydrophobic MTS as either an amino-terminal or a carboxyl-terminal extension. For the construction of plasmids pGEX-3X-MTS I and pGEX3X-MTS2, the following complementary oligonucleotides were synthesized:

20 MTS1 GATCGCAGCCGTTCTTCTCCCTGTTCTTGC CGCACCCGG CGTCGGCAAGAAGAGGGACAAGAACGCGTGGGCCCTAG (SEQ ID NO. 2)
MTS2 GATCCCCGCAGCCGTTCTTCTCCCTGTTCTTGC CGCACCCTAGC GGGCGTCGGCAAGAAGAGGGACAAGAACGGCGTGGATTGCTAG (SEQ ID NO. 3)

25 After annealing, the double-stranded MTS I and MTS2 oligonucleotides were ligated in BamHI digested pGEX-3X (Smith, D.B. and Johnson, K.S. 1988. Single-step

purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 67:31). DNA sequence analysis confirmed that in each plasmid the MTS coding sequence was correct and in-frame 5 with the GST coding sequence.

Construction of GST-Grb2SH2, GST-Grb2SH2-MTS, and GST-Stat1SH2-MTS expression plasmids.

A DNA fragment encoding the human Grb2 SH2 domain (amino acid residues 54-164) (Lowenstein, E.J., Daly, R.J.,

10 Batzer, A.G., U, W., Margolis, B., Lammers, R et al 1992.

The SH2 and SH3 domain-containing protein Grb2 links receptor tyrosine kinases to ras signaling. Cell 70:431) or the human Stat1 SH2 domain (residues 567-716)

(Schindler, C., Fu, X.-Y, Impnata, T., Aebersold, R., and

15 Darnell, J.E. Jr. 1992. Q. Proc. Natl Acad. Sci USA

89:7836) was synthesized from a Grb2 cDNA clone or a

Stat1 cDNA clone by PCR. The primers used for PCR, each containing BamHI sites at their 5'ends, were as follows:

Grb2 SH2: 5'-CCGGATCCCCGAAATGAAACCACATCCGTGGTTTTGGC

20 (SEQ ID NO. 4) and 5'-CCGGATCCC-

GAGGGCCTGGACGTATGTCGGCTGCTGTGG (SEQ ID NO. 5).

Stat1 SH2: 5'-CCGGATCCCCAACACCTGCTCCCTCTCTGGAATGATGGG

(SEQ ID NO. 6) and 5'-CCGGATCC-

CTCTAGAGGGTGAACCTCAGACACAGAAAT (SEQ ID NO. 7).

25 The PCR products were digested with BamHI and ligated in BamHI-digested pGEX-3X or pGEX-3XMTS2. DNA sequence analysis of the vector/insert junctions confirmed that

the GST-Grb2SH2, GST-Grb2SH2-MTS, and GST-Stat1SH2-MTS translational reading frames were maintained in each expression plasmid.

Expression of MTS Fusion protein

5 Expression and purification of GST fusion proteins. E. coli strain DH5α containing the appropriate expression plasmid 74 was grown in LB broth containing 100 µg/ml ampicillin at 37°C. GST fusion protein expression was induced by the addition of isopropyl ,β-D-thiogalactoside 10 (0.5 mM final concentration), and incubation at 37°C was continued for 2-3 hours. GST fusion proteins were purified from bacterial cell lysates by glutathione-agarose affinity chromatography. (Smith, D.B. and Johnson, K.S. 1988. Gene 67:31) except that after 15 sonication, cell lysates were cleared by centrifugation at 2000 x g for 5 minutes prior to mixing with glutathione-agarose beads. Protein preparations were concentrated by ultrafiltration using a PM10 membrane (Amicon, Beverly, MA) and stored at 4°C for immediate use 20 or -70°C for prolonged storage. Protein concentrations were determined spectrophotometrically at 280 nm. Immediately prior to their use in biological assays, protein concentrations were verified by SDS-PAGE using Coomassie brilliant blue staining intensity compared with 25 wild-type GST of known concentration. To confirm the amino acid content of the MTS in GST-MTS proteins, the MTS peptide was cleaved from glutathione-agarose bound

GST-MTSI with protease factor Xa essentially as described (Smith, D.B. and Johnson, K.S. 1988. Gene 67:31). The released MTS-containing peptide was purified by C₁₈ reverse-phase HPLC and characterized by mass spectrometry analysis as described (Smith, D.B. and Johnson, K.S. 1988. Gene 67:31). The released MTS-containing peptide was purified by C₁₈ reverse-phase HPLC and characterized by mass spectrometry as described (Lin, Y-Z., Yao, S., Veach, R.A., Torgerson, T.R., and Hawiger, J. 1995. J Biol Chem. 270:14255).

Example 5:

C3d -HEL fusion protein (taken from Dempsey et al.
Science, 271: 348, 1996)

15 The complimentary DNA encoding HEL, C3d (H. Domdey et
al Pro. Natl Acad Sci USA 79: 7619, 1982) dog
pre-pro-insulin signal sequence (M. E. Taylor and K.
Drickamer, Biochem. J. 274, 575 (1991), and the (G4S)₂
linker were amplified by polymerase chain reaction. The
epitope tag and stop codon were coded for by
20 oligonucleotide linkers. Fusion protein cassettes were
assembled in tandem: dog pre-pro-insulin signal sequence,
HEL, and one to three copies of C3d linked by (G₄S)₂ in
pSG5 (Stratagene). The HEL-C3d3 cassette was subcloned
into the A71d vector. The plasmids pSG.HEL, pSG.HEL.C3d,
25 and pSG.HEL.C3d2 were co-transfected with pSV2-neo into L
cells and A71d. HEL.C3d3 was transiently expressed in COS
cells. Recombinant proteins were purified by affinity

chromatography on YL 1/2 antibody (H. Skinner et al., J. Biol Chem. 266, 14163 1991) and fractionation on Sephacryl S-200 (Pharmacia).

Fusion tails are useful at the lab scale and have potential for enhancing recovery using economical recovery methods that are easily scaled up for industrial downstream processing. Fusion tails can be used to promote secretion of target proteins and can also provide useful assay tags based on enzymatic activity or antibody binding. Many fusion tails do not interfere with the biological activity of the target protein and in some cases have been shown to stabilize it. Nevertheless, for the purification of authentic proteins a site for specific cleavage is often included, allowing removal of the tail after recovery.

Fusion Tails for the recovery and purification of recombinant proteins. [adapted from Ford CF, Suominen I, Glatz CE (Protein Expr. Purif 2-3: 95-107, 1991]

The fusion protein of the present invention may also include a fusion tail such as has been developed to promote efficient recovery and purification of recombinant proteins from crude cell extracts or culture media. In these systems, a target protein is genetically engineered to contain a C- or N-terminal polypeptide tail, which provides the biochemical basis for specificity in recovery and purification. Tails with a variety of characteristics have been used:

(1) entire enzymes with affinity for immobilized substrates or inhibitors;

(2) peptide-binding proteins with affinity to immunoglobulin G or albumin;

5 (3) carbohydrate-binding proteins or domains;

(4) a biotin-binding domain for in vivo biotination promoting affinity of the fusion protein to avidin or streptavidin;

(5) antigenic epitopes with affinity to immobilized monoclonal antibodies;

10 (6) poly(His) residues for recovery by immobilized metal affinity chromatography; and

(7) other poly(amino acid)s, with binding specificity based on properties of the amino acid side chain.

15 Fusion tails are useful at the lab scale and have potential for enhancing recovery using economical recovery methods that are easily scaled up for industrial downstream processing. Fusion tails can be used to promote secretion of target proteins and can also provide

20 useful assay tags based on enzymatic activity or antibody binding. Many fusion tails do not interfere with the biological activity of the target protein and in some cases have been shown to stabilize it. Nevertheless, for the purification of authentic proteins, a site for

25 specific cleavage is often included, allowing removal of the tail after recovery.

The present invention describes the generation of an antibody-peptide fusion protein that enhances the

biological and immunological activity of the antibody without changing the antibody specificity for the corresponding antigen. In the genetically engineered fusion protein mimics the chemically engineered chimeric antibodies described in Patent Application Serial No. 5 09/070,907. Specifically, the present invention provides the generation of antibody fusion proteins containing the complete or partial autophilic 24mer peptide, the membrane transport peptide (MTS) or the C3d peptide, all described 10 above.

The invention also provides a composition and a pharmaceutical composition comprising a fusion protein made up of (1) an antibody and (2) a peptide having a biological activity selected from the group consisting of 15 immuno-stimulatory, membrane transport and homophilic activities wherein the peptide is connected by peptide bonds to the antibody at a site that does not interfere with antigen binding of the antibody.

Any antibody may be used in the peptide/antibody 20 complex of the invention. Preferred antibodies are anti-idiotype antibodies. For example, anti-idiotype antibody 3H1 may be used (see "Anti-idiotype Antibody Vaccine 25 (3H1) that Mimics the Carcinoembryonic Antigen (CEA) as an Adjuvant Treatment", Foon, et al., *Cancer Weekly*, June 24, 1996). Other anti-idiotype antibodies which may be used in the present invention include, for example, anti-idiotype antibody to chlamydia glycolipid exoantigen (U.S. Patent No. 5,656,271; anti-idiotype antibody 1A7

for the treatment of melanoma and small cell carcinoma (U.S. Patent No. 5,612,030); anti-idiotype antibody MK2-23 anti-melanoma antibody (U.S. Patent No. 5,493,009); anti-idiotypic gonococcal antibody (U.S. Patent No. 5,476,784) *Pseudomonas aeruginosa* anti-idiotype antibody (U.S. Patent No. 5,233,024); antibody against surface Ig of Human B cell tumor (U.S. Patent No. 4,513,088); and monoclonal antibody BR96 (U.S. Patent No. 5,491,088). Any restrictions on peptide length are those practical 10 limitations associated with peptide synthesis and not restrictions associated with practice of the method of the invention.

Additionally, self-binding peptides such as those disclosed in (Kang, C.Y. Brunck, T.K., Kiever-Emmons, T., Blalick, J.E. and Kohler, H., "Inhibition of self-binding 15 proteins (auto-antibodies) by a VH-derived peptide, *Science*, 240: 1034-1036, 1988, incorporated herein by reference in its entirety) used in the method of the present invention.

Additionally, signal peptides such as those disclosed 20 in Roias, et al., "Genetic Engineering of proteins with cell membrane permeability", *Nature Biotechnology*, 16: 370-375 (1988) and Calbiochem Signal Transduction Catalogue 1997/98, incorporated herein by reference in 25 their entireties, may be used in the method of the invention.

The peptide may be designed to have inverse hydropathic character and exhibits mutual affinity and

homophilic (self) binding within the peptide, in accordance with the disclosure of United States Patent No. 5,523,208 (incorporated herein by reference in its entirety).

5 The compositions of the invention are useful in pharmaceutical compositions for systemic administration to humans and animals in unit dosage forms, sterile solutions or suspensions, sterile non-parenteral solutions or suspensions oral solutions or suspensions, 10 oil in water or water in oil emulsions and the like, containing suitable quantities of an active ingredient. Topical application can be in the form of ointments, creams, lotions, jellies, sprays, douches, and the like. The compositions are useful in pharmaceutical 15 compositions (wt%) of the active ingredient with a carrier or vehicle in the composition in about 1 to 20% and preferably about 5 to 15%.

20 The above parenteral solutions or suspensions may be administered transdermally and, if desired a more concentrated slow release form may be administered. The cross-linked peptides of the invention may be 25 administered intravenously, intramuscularly, intraperitoneally or topically. Accordingly, incorporation of the active compounds in a slow release matrix may be implemented for administering transdermally. The pharmaceutical carriers acceptable for the purpose of this invention are the art known carriers that do not adversely affect the drug, the host, or the

material comprising the drug delivery device. The carrier may also contain adjuvants such as preserving stabilizing, wetting, emulsifying agents and the like together with the penetration enhancer of this invention.

5 The effective dosage for mammals may vary due to such factors as age, weight activity level or condition of the subject being treated. Typically, an effective dosage of a compound according to the present invention is about 10 to 500mg, preferably 2-15 mg, when administered by 10 suspension at least once daily. Administration may be repeated at suitable intervals.

The purpose of the above description and examples is to illustrate some embodiments of the present invention without implying any limitation. It will be apparent to 15 those of skill in the art that various modifications and variations may be made to the composition and method of the present invention without departing from the spirit or scope of the invention. All patents and publications cited herein are incorporated by reference in their 20 entireties.